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Abstract
Malignant brain tumors are a significant health problem in children and adults and are often
unmanageable. As a metabolic disorder involving the dysregulation of glycolysis and respiration,
malignant brain cancer is potentially manageable through changes in metabolic environment. A
radically different approach to brain cancer management is proposed that combines metabolic
control analysis with the evolutionarily conserved capacity of normal cells to survive extreme shifts
in physiological environment. In contrast to malignant brain tumors that are largely dependent on
glycolysis for energy, normal neurons and glia readily transition to ketone bodies (β-
hydroxybutyrate) for energy in vivo when glucose levels are reduced. The bioenergetic transition
from glucose to ketone bodies metabolically targets brain tumors through integrated anti-
inflammatory, anti-angiogenic, and pro-apoptotic mechanisms. The approach focuses more on the
genomic flexibility of normal cells than on the genomic defects of tumor cells and is supported from
recent studies in orthotopic mouse brain tumor models and in human pediatric astrocytoma
treated with dietary energy restriction and the ketogenic diet.
Introduction
The world-wide incidence of malignant brain tumors may
be increasing in both children and the elderly [1-4].
Regardless of these ominous findings, the standard thera-
pies for malignant gliomas (surgical resection and radia-
tion) are basically the same today as they have been for
over five decades [5-7]. While these therapies may retard
glioma growth over the short term, they can facilitate gli-
oma recurrence and enhance growth rate over the longer
term through alterations in morphogenetic fields [8,9].
Chemotherapy has little long-term benefit on most malig-
nant gliomas and is often associated with adverse effects
that diminish the length or quality of life [7,10]. The ther-
apeutic targeting of brain tumor-associated mutations
may also be problematic as most tumor mutations arise as
epiphenomena of tissue disorganization and their rela-
tionship to causality is uncertain [8,11,12]. Despite mod-
est gains in survival with temozolomide chemotherapy,
few things are more certain in the brain tumor field than
the impotence of most current therapies [2,7,13]. Hence,
new approaches are needed that can provide long-term
management of malignant brain tumors while permitting
a decent quality of life.
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Metabolic Control Analysis
Metabolic control analysis evaluates the degree of flux in
metabolic pathways and can be used to analyze and treat
complex diseases [14-16]. The approach is based on find-
ings that compensatory genetic and biochemical path-
ways regulate the bioenergetic potential of cells and
ultimately the phenotype [14,15,17]. As rate-controlling
enzymatic steps in biochemical pathways are dependent
on the metabolic environment of the physiological sys-
tem, the management of disease phenotype depends
more on the flux of the entire system than on the expres-
sion of any specific gene or enzyme alone [16-19]. In
other words, complex disease phenotypes can be man-
aged through self-organizing networks that display system
wide dynamics involving glycolysis and respiration. Glo-
bal manipulations of these metabolic networks can
restore orderly adaptive behavior to widely disordered
states involving complex gene-environmental interactions
[15,17,20,21].
As abnormal energy metabolism and biological chaos are
characteristics of brain tumors [8,22-24], the general prin-
ciples of metabolic control analysis can be effective for
brain cancer management. This hypothesis is based on the
known differences in energy metabolism between normal
and neoplastic brain cells. As long as brain tumors are
provided a physiological environment conducive for their
glycolytic energy needs, they will survive; when this envi-
ronment is restricted or abruptly changed, they will either
growth arrest or perish. Here we describe how new thera-
peutic approaches, which lower circulating glucose and
elevate ketone bodies (acetoacetate and β-hydroxybu-
tyrate), target brain tumors while enhancing the meta-
bolic efficiency of normal neurons and glia.
Energy Metabolism in Normal Brain Cells
To manage brain cancer through metabolic targeting it is
necessary to consider energy metabolism in the normal
orthotopic tissue. Figure 1 illustrates some of the meta-
bolic pathways discussed here. Under normal physiologi-
cal conditions, the mature brain derives almost all of its
energy from the aerobic oxidation of glucose [15,25,26].
The glucose transporter, GLUT-1, is enriched in the brain
capillary endothelial cells and mediates the facilitated dif-
fusion of glucose through the blood brain barrier. Most of
the glucose is metabolized to pyruvate, which enters the
mitochondria of neurons and glia and is converted to
acetyl-CoA before entering the TCA cycle. Only about
13% of glycolytic pyruvate is converted to lactate under
normal conditions [26]. Fatty acids are attached to lipo-
proteins and do not pass the blood brain barrier as fuel
substrates, though octanoate may be an exception [26-
28]. It is also unlikely that lactate is used for energy metab-
olism in adult brain, but this remains somewhat contro-
versial [26,29-31]. Hence glucose is the primary, if not
exclusive, brain metabolic fuel under normal physiologi-
cal conditions.
While glucose is the preferred energy substrate, neurons
and glia will metabolize ketones for energy under fasting-
induced reductions of blood glucose. This is a conserved
physiological adaptation to prolonged food restriction
and evolved to enhance survival and maintain adequate
brain function while sparing proteins [15,27,32-34].
Ketone bodies, consisting of acetoacetate, and β-hydroxy-
butyrate (β-OHB) are derived from fat catabolism in the
liver and their concentration in blood is inversely related
to that of glucose [21,35-37]. Ketone bodies are trans-
ported into the brain through the blood-brain barrier
monocarboxylic transporters (MCTs), whose expression is
regulated in part by circulating ketone and glucose levels
[30,31,34,38-41].  β-OHB is the predominant blood
ketone body and is rapidly oxidized to acetyl-CoA in the
mitochondria through an enzymatic series involving 3-
hydroxybutyrate dehydrogenase, SCOT (succinyl-CoA-
acetoacetate-CoA transferase), and mitochondrial acetyl-
CoA thiolase [33,34,42,43]. Acetone is a non-enzymatic
byproduct of ketone body synthesis and is largely excreted
in the urine or exhaled from the lungs [34,44].
Although the levels of glucose and ketones in brain are
proportional to their levels in blood [34,45], the adult
brain does not usually metabolize ketone bodies for
energy unless blood glucose levels are reduced [36]. Ther-
apeutic efficacy of the ketogenic diet is best when coupled
to dietary energy restriction under which conditions circu-
lating glucose levels are gradually reduced in conjunction
with elevations of ketone bodies [15,21]. The emphasis
here is on the term "gradual", as ketone bodies cannot be
used for energy following acute hypoglycemia [46]. The
situation is different, however, for in vitro preparations
where neuronal glial interactions are disrupted and the
blood brain barrier is absent [47,48]. The gradual transi-
tion from glucose to ketone bodies for energy in vivo
requires a flexible genome for the coordinated integration
of multiple metabolic networks according to principles of
metabolic control analysis [15,36].
Ketone bodies are more energetically efficient than either
pyruvate or fatty acids because they are more reduced
(greater hydrogen/carbon ratio) than pyruvate and do not
uncouple the mitochondrial proton gradient as occurs
with fatty acid metabolism [14]. In contrast to glucose,
ketone bodies by-pass cytoplasmic glycolysis and directly
enter the mitochondria where they are oxidized to acetyl-
CoA [44,49]. The amount of acetyl-CoA formed from
ketone body metabolism is also greater than that formed
from glucose metabolism [50]. This increases TCA cycle
metabolites (from citrate to α-ketoglutarate) while reduc-
ing the mitochondrial NAD couple, [NAD+]/[NADH],Nutrition & Metabolism 2005, 2:30 http://www.nutritionandmetabolism.com/content/2/1/30
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and increasing the mitochondrial Q couple [Q]/[QH2]
[14,50]. The difference between these couples increases
the redox span between the NADH dehydrogenase com-
plex (site I), and the CoQH2-cytochrome C reductase (site
III) thus enhancing the mitochondrial proton gradient
[14]. This enhances the energy available from the hydrol-
ysis of ATP, ∆G'ATP, the cell's key energy reserve generated
through the mitochondrial Fl ATPase [14,16]. Remarka-
bly, the ketone body-induced increase in the ∆G'ATP is
also accomplished using less oxygen [48,50]. These and
other findings led Veech to designate ketone bodies as a
"super fuel" [14].
Ketones and Free Radicals
In addition to increasing ATP production while reducing
oxygen consumption, ketone body metabolism can also
reduce production of damaging free radicals [14,16,48].
The semiquinone of Q, the half reduced form, spontane-
ously reacts with oxygen and is the major source of mito-
chondrial free radical generation [14,51]. Oxidation of
the Q couple reduces the amount of the semiquinone
form thus decreasing superoxide production [14]. Since
the cytosolic free NADP+/NADPH concentration couple is
in near equilibrium with the glutathione couple, ketone
body metabolism will increase the reduced form of glu-
Perspectives on the metabolic management of brain cancer through a dietary reduction of glucose and elevation of ketone  bodies Figure 1
Perspectives on the metabolic management of brain cancer through a dietary reduction of glucose and eleva-
tion of ketone bodies. A dietary reduction in circulating glucose will increase ketone utilization for energy in normal neurons 
and glia. This will induce an energy transition from glycolysis to respiration. Cancer cells however, may be unable to transition 
from glucose to ketones due to alterations in mitochondrial structure or function (dashed lines). The double slash indicates a 
disconnection between glycolysis and respiration according to the Warburg hypothesis. Abbreviations: GLUT-1 (glucose trans-
porter), MCT-1 (monocarboxylate transporter), SCOT (succinyl-CoA-acetoacetate-CoA transferase), β-OHB (β-hydroxybu-
tyrate), β-HBDH (β-hydroxybutyrate dehydrogenase).
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tathione thus facilitating destruction of hydrogen perox-
ide [14]. The reduction of free radicals through ketone
body metabolism will also reduce tissue inflammation
provoked by reactive oxygen species. Thus, ketone bodies
are not only a more efficient metabolic fuel than glucose,
but also possess anti-inflammatory potential.
Energy Metabolism in Brain Tumors
In contrast to normal brain that oxidizes glucose as well as
ketone bodies for energy, malignant brain tumors from
either humans or animal models lack metabolic flexibility
and are largely dependent on glucose for energy
[21,23,52-58]. Enhanced glycolysis produces excess lactic
acid that can return to the tumor as glucose through the
Cori cycle [59] (Figure 1). Although some neural tumors
metabolize ketone bodies, this metabolism is largely for
lipid synthesis rather than for energy production [60,61].
Many tumors also have reduced activity of SCOT, the rate-
controlling step for utilizing β-OHB as a respiratory fuel
[42,62,63]. Consistent with these observations, we
recently found that β-OHB could rescue normal mouse
astrocytes under low glucose conditions, but could not
rescue mouse astrocytoma cells [20]. Although glutamine
may provide energy to some non-neural tumors,
glutamine stimulates glycolysis in C6 rat glioma cells and
may not serve as a direct respiratory fuel [64]. Hence brain
tumors, like most malignant tumors, depend heavily on
glucose and glycolysis for their metabolic energy and are
generally unable to metabolize β-OHB for energy.
In addition to glycolytic dependence, most tumors includ-
ing brain tumors, express abnormalities in the number
and function of their mitochondria [65,66]. Such abnor-
malities would prevent the bioenergetic utilization of
ketone bodies, which require functional mitochondria for
their oxidation [47]. Warburg originally emphasized that
the high glycolytic rate of tumors resulted from dimin-
ished or disturbed respiration [67,68]. While most cells
die from damaged respiration, those cells that can
enhance and modify their anaerobic glycolysis in
response to respiratory damage will survive and form
tumors [67,68]. Later studies in a variety of neural and
non-neural tumor systems showed that these respiratory
disturbances involve abnormalities in TCA cycle compo-
nents, alterations in electron transport, and deficiencies in
oxidative phosphorylation [23,55,69-71]. Mitochondrial
DNA mutations, however, may not be involved [12].
Structural defects of the inner mitochondrial membrane,
that would reduce or dissipate the proton motive gradi-
ent, could also prevent normal ATP production despite
the appearance of oxidative metabolism, i.e., oxygen con-
sumption and CO2 production [70,72,73]. Considered
together, these findings indicate that brain tumors suffer
from reduced respiratory capacity coupled to an increased
glycolysis and lactic acid production.
Although persistent aerobic glycolysis (glycolysis in the
presence of oxygen) or defects in the Pasteur effect (reduc-
tion of glycolysis in the presence of oxygen) are character-
istics of many tumors, Warburg considered these
phenomena too labile or too dependent on environmen-
tal conditions to be reliable indicators of tumor metabo-
lism [68]. Rather, he emphasized the importance of
defects in the coordination of glycolysis with respiration.
The latency between tumor initiation and progression was
considered the period necessary to disconnect respiration
from glycolysis [68]. Recent studies in human glioblast-
oma cells suggest that this disconnect involves activation
of the Akt oncogene rendering cancer cells dependent on
aerobic glycolysis for continued growth and survival [74].
This is consistent with the Warburg hypothesis that the
increased glycolysis of tumor cells occurs gradually in
order to compensate for respiratory failure [68]. In con-
trast to normal brain cells, in which glycolysis and respi-
ration are tightly coupled, tumor cells are defective in their
ability to integrate energy metabolism between glycolysis
and respiration [71]. It is these defects that will render
brain tumor cells vulnerable to metabolic targeting
through metabolic control analysis. Support for this pos-
sibility comes from studies with the ketogenic diet and
dietary energy restriction.
Dietary Energy and Brain Cancer
The Ketogenic Diet
In 1995, Nebeling and coworkers attempted the first
nutritional metabolic therapy for human malignant brain
cancer using the ketogenic diet [75]. The ketogenic diet
(KD) is a high fat low carbohydrate diet that has been
used for decades as an effective therapy for refractory sei-
zures in children [15,76,77]. The objective of the Nebe-
ling study was to shift the prime substrate for energy
metabolism from glucose to ketone bodies in order to dis-
rupt tumor metabolism while maintaining the nutritional
status of patients [75].
The patients in this landmark clinical study included two
female children with nonresectable advanced grade brain
tumors (anaplastic astrocytoma stage IV, and cerebellar
astrocytoma stage III) [75]. Measurable tumor remained
in both subjects following extensive radiation and chem-
otherapy. Although severe life threatening adverse effects
occurred from the radiation and chemotherapy, both chil-
dren responded remarkably well to the KD and experi-
enced long-term tumor management without further
chemo or radiation therapy [75]. Indeed, one of the
patients is still alive and well at the time of this writing
(Nebeling, personal communication). Positron Emission
Tomography with fluro-deoxy-glucose (FDG-PET) also
showed a 21.8% reduction in glucose uptake at the tumor
site in both subjects on the KD [75].Nutrition & Metabolism 2005, 2:30 http://www.nutritionandmetabolism.com/content/2/1/30
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Despite the logic of these studies and the dramatic find-
ings, no further human studies or clinical trials have been
conducted on the therapeutic efficacy of the KD for brain
cancer. The reason for this is not clear but may reflect a
preference of the major Brain Tumor Consortia for using
"hand-me-down" drug therapies from other cancer stud-
ies rather than exploring more effective biological or non-
chemotherapeutic approaches [7]. This is unfortunate as
our recent findings in brain tumor animal models show
that the therapeutic potential of the restricted KD, involv-
ing reduced glucose and elevated β-OHB, is likely to be
greater than that for any current brain tumor chemother-
apy [20]. Moreover, the KD would eliminate or reduce the
need for adjuvant anticonvulsant and steroidal medica-
tions for brain tumor patients as the KD has antiepileptic
and anticonvulsant effects and, when restricted in caloric
intake, will naturally elevate circulating glucocorticoid
levels [15,77-80]. These findings suggest that the KD
would be an effective multifactorial diet therapy for
malignant brain cancer and should be considered as an
alternative therapeutic option.
Dietary Energy Restriction
The findings of the Nebeling group were recently con-
firmed in a series of orthotopic mouse brain tumor mod-
els treated with the KD and dietary energy restriction
[21,37,81,82]. As with the KD, dietary energy restriction
(DR) reduces glucose and elevates ketone bodies. Indeed,
the DR-induced inhibition of brain tumor growth is
directly correlated with reduced levels of glucose and ele-
vated levels of ketone bodies [20,21]. This energy transi-
tion contributes to the powerful anti-angiogenic effects of
DR [81,82]. As a natural dietary therapy, DR improves
health, prevents tumor formation, and reduces inflamma-
tion [83-88]. DR also improves mitochondrial respiratory
function and glutathione redox state in normal cells
[87,89]. Thus, DR naturally inhibits glycolysis and tumor
growth while enhancing the health and vitality of normal
cells and tissues.
The anti-angiogenic effects of DR arise from reduced
tumor energy metabolism [21,37,81,82]. This is impor-
tant since the angiogenic properties of most human glio-
mas are closely linked to metabolic activity [90]. Previous
studies showed that the antitumor effects of DR result
from caloric restriction per se and not from the restriction
of any specific dietary component such as proteins, vita-
mins, minerals, fats, or carbohydrates [21,88,91,92]. DR
or fasting can also reduce cerebral blood flow and oxygen
consumption that would further stress brain tumor cells
already weakened from reduced glucose levels [33].
Besides reducing angiogenesis, DR also increases brain
tumor apoptosis [81,82]. The proapoptotic effects of DR
occur in large part from reduced glycolytic energy that
most tumors rely upon for growth.
A reduction in glycolytic energy would reduce lactate lev-
els and hydroxyl radical production. This is important
since lactate and hydroxyl radicals enhance tumor inflam-
mation as well as cytokine production (tumor necrosis
factor α, interleukin-6, and -1β) through glial activation
(microglia and astroglia) [93,94]. DR also reduces inflam-
mation and the inflammatory properties of macrophages,
while enhancing their phagocytic activities [86,95]. An
uncoupling of the detrimental inflammatory properties of
tumor associated macrophages from their beneficial
phagocytic properties (to remove tumor cell corpses) is
considered essential for the eventual management of
brain cancer [8]. Hence diet therapies, which lower glu-
cose availability and elevate ketone bodies, can reduce
brain tumor growth through integrated anti-inflamma-
tory, anti-angiogenic and pro-apoptotic mechanisms.
Metabolic Control of Brain Cancer: An 
Evolutionary Perspective
Based on the differences in energy metabolism between
normal brain cells and brain tumor cells, we propose a
radically different approach to brain cancer management
that combines metabolic control analysis with the evolu-
tionarily conserved capacity of normal cells to survive
extreme shifts in physiological environment. The adapta-
tion to environmental extremes is conserved within the
genome according to the ecological instability theory of
Potts [96]. Consequently, only those cells with a flexible
genome will be capable of surviving abrupt changes in
metabolic landscape. Cells with genomic defects, which
would limit flexibility, should be less adaptable to meta-
bolic stress and therefore vulnerable to elimination
through principles of metabolic control analysis. This
strategy focuses more on the genetic capabilities of nor-
mal cells than on the genetic defects of tumor cells.
As a metabolic disorder involving the dysregulation of gly-
colysis and respiration, brain cancer is potentially man-
ageable through abrupt changes in metabolic
environment. Significant cellular energy is used to main-
tain the activity of transmembrane ion pumps (the Na+,
K+-ATPase and Ca2+ and Mg2+ ATPases) [29,97,98] (Figure
1). The amount of energy needed to maintain pump func-
tion is also greater than that needed for mitosis, which is
largely dependent on glycolytic energy [70,97]. Despite
differences in membrane potential, most cells have a con-
stant ∆G' of about -57 kJ/mol [14]. According to Veech
this is "the still point in the turning world" and if cells
cannot maintain this useable ATP they lose potassium,
gain sodium and calcium, swell, and eventually die [16].
In other words, regardless of whether the cell is a normal
neuron, a glial cell, or even a transformed tumor cell, its
survival depends on maintaining an adequate ∆G' of ATP
hydrolysis. Tumor cells with limited genomic flexibility
should therefore be less capable than normal cells inNutrition & Metabolism 2005, 2:30 http://www.nutritionandmetabolism.com/content/2/1/30
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utilizing alternative energy substrates to maintain their
∆G' of ATP hydrolysis.
The energy used to maintain pump function and cell via-
bility in normal brain cells comes from either glycolysis or
aerobic respiration [29,99]. In the case of C6 glioma cells
and most brain tumors for that mater, this energy is
mostly derived from glycolysis [29,99]. This would then
render brain tumor cells vulnerable to reductions in circu-
lating glucose levels as these mutant cells would have dif-
ficulty oxidizing alternative fuels (ketone bodies) through
respiration. While some brain tumor cells may survive
through up-regulation of their glucose transporters
[100,101], most will either perish or reduce their growth.
Direct support for this hypothesis comes from our recent
findings in experimental mouse brain tumor models and
from those of Nebeling and co-workers in human pediat-
ric astrocytoma [20,37,75,81].
The widely held notion that brain tumor cells are some-
how hardy or tough and resistant to death (programmed
or nonprogrammed) may be a misconception. How can
brain tumor cells, or any tumor cell for that matter, that
have multiple types and kinds of genetic mutations be
more fit and hardy than normal cells that possess a flexi-
ble genome and can easily transition between glycolysis
and respiration for energy maintenance? The notion that
tumor cells are more versatile than nontumor cells is also
illogical in the context of evolutionary biology. While
knowledge of tumor-associated mutations and genomic
instability is of considerable academic interest, this infor-
mation has produced no new or effective clinical therapies
for brain tumors. Regardless of when or how genomic
defects become involved in the initiation or progression
of brain tumors, these defects can be exploited for the
metabolic destruction of the tumor.
Normal cells evolved to survive extremes in metabolic and
physiological environment due largely to oscillatory
changes in the physical environment [96]. Moreover, the
ability to adapt to extreme environmental stress is
retained within the normal flexible genome [19,102]. It is
this flexibility that allows normal brain cells to transition
from glucose to β-OHB for energy under reduced energy
availability. Due to accumulated nuclear genetic muta-
tions and respiratory defects, brain tumor cells will be less
adaptable than normal cells to abrupt changes in meta-
bolic environment and can be either destroyed outright or
isolated metabolically from normal cells. Hence, the
genomic and metabolic flexibility of normal brain cells
can be used to target indirectly the genetically defective
and less metabolically flexible brain tumor cells.
According to this hypothesis, a novel strategy can be sug-
gested for human brain tumor management that
enhances the respiratory potential of normal brain cells
while metabolically targeting the tumor cells. The
approach would involve a sequential series of therapeutic
steps and should be effective against any primary or sec-
ondary brain tumor regardless of cell of origin, anatomi-
cal location, or histological grade. Step one would lower
circulating glucose levels and elevate circulating β-OHB
levels through diet therapies or ketone body supplemen-
tation. Glucose ranges between 3.0–3.5 mM (55–65 mg/
dl) and β-OHB ranges between 4–5 mM should be effec-
tive for tumor management in most patients. The condi-
tions for these parameters have been described previously
for children and adults and can be adjusted on a case-by-
case basis [34,35,75,103]. These values are also well
within normal physiological ranges and will have antian-
giogenic and proapoptotic effects causing metabolic isola-
tion and significant tumor shrinkage that can be assessed
from imaging analysis. Reduced glucose and elevated
ketones could also antagonize tumor cachexia as previ-
ously mentioned [82].
Step two would involve surgical resection if necessary.
Smaller brain tumors with reduced vascularity and clearly
circumscribed boundaries should be easier to resect than
larger brain tumors with poorly circumscribed boundaries
and extensive vascularization [104]. The diet therapy
could also be adjusted following surgery to facilitate heal-
ing and to maintain metabolic pressure on any surviving
tumor cells.
Finally, step three could involve the use of either conven-
tional or novel targeted therapies. While these therapeutic
approaches might have little if any long-term benefit on
malignant brain tumor management if used initially, they
could be highly effective following the step one strategy
after the tumor cells are weakened and metabolically iso-
lated from the physiologically strengthened normal brain
cells. Moreover, glycolysis inhibitors that would adversely
affect normal cells might also be more effective following
the first two steps of the proposed therapeutic strategy
[105-109]. It is also possible that carefully executed
weight cycling strategies could maintain metabolic pres-
sure on surviving tumor cells and facilitate their eradica-
tion or growth retardation [110]. In addition to global
diet therapies, more specific amino acid restrictions could
also be effective in eliminating surviving tumor cells
[111].
The objective of this new brain tumor therapeutic
approach is to consistently change the physiological and
metabolic environment of the tumor and the host. Only
those cells with a normal flexible genome, honed through
millions of years of environmental forcing and variability
selection, are expected to survive extreme shifts in meta-
bolic environment. Indeed, extreme conditions of survivalNutrition & Metabolism 2005, 2:30 http://www.nutritionandmetabolism.com/content/2/1/30
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and fitness will test the limits of a cell population's persist-
ence in any given location over time [96]. While some
brain tumor cells might survive under one restricted envi-
ronment or another, it is unlikely that all tumor cells will
survive all restricted environments. In other words, it is
the theory of Potts applied with sustained pressure to the
entire population of normal and neoplastic brain cells.
We predict that this therapeutic approach will be more
successful than current approaches because it is based on
the principles of evolutionary biology and metabolic con-
trol analysis.
Abbreviations
KD, ketogenic diet; SCOT, succinyl-CoA-acetoacetate-CoA
transferase; β-OHB, β-hydroxybutyrate; TCA, tricarboxylic
acid.
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